NanoViricides, Inc. announced today that it has signed a pre-clinical study agreement for the evaluation of FluCide, NanoViricides; universal anti-influenza drug candidate. The study will be conducted by Thevac, LLC, a spin-off of the Louisiana State University.
Molecular Imprints, Inc. today announced an expansion plan that includes increasing its workforce with the addition of 30-50 employment opportunities during 2009 and expanding the scale of its facilities by more than a third.
Maintaining sustainable and successful business during the global economic crisis: The newly published Sustainable Development Report 2008 contains information on the strategies pursued and programs implemented by the Bayer Group to achieve this goal.
Z-Cube Srl, the corporate venture arm of Zambon Company SpA, and Yissum Research Development Company Ltd., the technology transfer company of the Hebrew University of Jerusalem, announced today that they have entered into a license agreement for Z-Cube to develop and commercialize an innovative nanotechnology drug delivery system for the treatment of pain.
In conjunction with the Intersolar 2009 tradeshow being held in Munich from May 27-29, Applied Materials is hosting a press event with solar industry experts to discuss how these proposed new policies will shape the future of solar power and open new markets, including the vast and fragmented American utility market.
Cancer Therapeutics, Inc., an emerging biotechnology business incubator with a specific emphasis on disruptive cancer treatments and nanotechnology, announced today it anticipates a definitive agreement to acquire a minority ownership share of NanoTherapies, LLC will be finalized by the end of this month.
Seattle-based Modumetal, Inc has announced a formal agreement with Austria-based Happy Plating to leverage the company?s experience and electrochemical manufacturing infrastructure to create a European commercial manufacturing base for Modumetal?s advanced nanolaminated coatings.
NanoSight announces their close involvement in the research and development of a new generation of novel instrumentation and methodologies aimed at measuring cellular nanoparticles in plasma and urine as biomarkers of a broad range of human disease conditions.